|
1
|
Patel R and Hyer W: Practical management
of polyposis syndromes. Frontline Gastroenterol. 10:379–387. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bisgaard ML, Fenger K, Bülow S, Niebuhr E
and Mohr J: Familial adenomatous polyposis (FAP): Frequency,
penetrance, and mutation rate. Hum Mutat. 3:121–125. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Aretz S, Uhlhaas S, Caspari R, Mangold E,
Pagenstecher C, Propping P and Friedl W: Frequency and parental
origin of de novo APC mutations in familial adenomatous polyposis.
Eur J Hum Genet. 12:52–58. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vasen HFA, Möslein G, Alonso A, Aretz S,
Bernstein I, Bertario L, Blanco I, Bülow S, Burn J, Capella G, et
al: Guidelines for the clinical management of familial adenomatous
polyposis (FAP). Gut. 57:704–713. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kudo S, Kashida H, Nakajima T, Tamura S
and Nakajo K: Endoscopic diagnosis and treatment of early
colorectal cancer. World J Surg. 21:694–701. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Minamoto T, Sawaguchi K, Mai M, Yamashita
N, Sugimura T and Esumi H: Infrequent K-ras activation in
superficial-type (flat) colorectal adenomas and adenocarcinomas.
Cancer Res. 54:2841–2844. 1994.PubMed/NCBI
|
|
7
|
Kudo S: Endoscopic mucosal resection of
flat and depressed types of early colorectal cancer. Endoscopy.
25:455–461. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kudo SE, Takemura O and Ohtsuka K: Flat
and depressed types of early colorectal cancers: From East to West.
Gastrointest Endosc Clin N Am. 18581–593. (xi)2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hiraoka S, Kato J, Tatsukawa M, Harada K,
Fujita H, Morikawa T, Shiraha H and Shiratori Y: Laterally
spreading type of colorectal adenoma exhibits a unique methylation
phenotype and K-ras mutations. Gastroenterology. 131:379–389. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sakai E, Ohata K, Chiba H, Matsuhashi N,
Doi N, Fukushima J, Endo H, Takahashi H, Tsuji S, Yagi K, et al:
Methylation epigenotypes and genetic features in colorectal
laterally spreading tumors. Int J Cancer. 135:1586–1595. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sakai E, Fukuyo M, Matsusaka K, Ohata K,
Doi N, Takane K, Matsuhashi N, Fukushima J, Nakajima A and Kaneda
A: TP53 mutation at early stage of colorectal cancer progression
from two types of laterally spreading tumors. Cancer Sci.
107:820–827. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tomita N, Ishida H, Tanakaya K, Yamaguchi
T, Kumamoto K, Tanaka T, Hinoi T, Miyakura Y, Hasegawa H, Takayama
T, et al: Japanese society for cancer of the colon and rectum
(JSCCR) guidelines 2020 for the clinical practice of hereditary
colorectal cancer. Int J Clin Oncol. 26:1353–1419. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Horak P, Griffith M, Danos AM, Pitel BA,
Madhavan S, Liu X, Chow C, Williams H, Carmody L, Barrow-Laing L,
et al: Standards for the classification of pathogenicity of somatic
variants in cancer (oncogenicity): Joint recommendations of
clinical genome resource (ClinGen), cancer genomics consortium
(CGC), and variant interpretation for cancer consortium (VICC).
Genet Med. 24:986–998. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Song M and Chan AT: Environmental factors,
gut microbiota, and colorectal cancer prevention. Clin
Gastroenterol Hepatol. 17:275–289. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Metz AJ, Bourke MJ, Moss A, Dower A,
Zarzour P, Hawkins NJ, Ward RL and Hesson LB: A correlation of the
endoscopic characteristics of colonic laterally spreading tumours
with genetic alterations. Eur J Gastroenterol Hepatol. 25:319–326.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sugimoto T, Ohta M, Ikenoue T, Yamada A,
Tada M, Fujishiro M, Ogura K, Yamaji Y, Okamoto M, Kanai F, et al:
Macroscopic morphologic subtypes of laterally spreading colorectal
tumors showing distinct molecular alterations. Int J Cancer.
127:1562–1569. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sugai T, Habano W, Takagi R, Yamano H,
Eizuka M, Arakawa N, Takahashi Y, Yamamoto E, Kawasaki K, Yanaiet
S, et al: Analysis of molecular alterations in laterally spreading
tumors of the colorectum. J Gastroenterol. 52:715–723. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Grim JE, Knoblaugh SE, Guthrie KA, Hagar
A, Swanger J, Hespelt J, Delrow JJ, Small T, Grady WM, Nakayama KI
and Clurman BE: Fbw7 and p53 cooperatively suppress advanced and
chromosomally unstable intestinal cancer. Mol Cell Biol.
32:2160–2167. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yokobori T, Mimori K, Iwatsuki M, Ishii H,
Onoyama I, Fukagawa T, Kuwano H, Nakayama KI and Mori M:
p53-Altered FBXW7 expression determines poor prognosis in gastric
cancer cases. Cancer Res. 69:3788–3794. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wood LD, Parsons DW, Jones S, Lin J,
Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, et al: The
genomic landscapes of human breast and colorectal cancers. Science.
318:1108–1113. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sjöblom T, Jones S, Wood LD, Parsons DW,
Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, et al:
The consensus coding sequences of human breast and colorectal
cancers. Science. 314:268–274. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mao JH, Perez-Losada J, Wu D, Delrosario
R, Tsunematsu R, Nakayama KI, Brown K, Bryson S and Balmain A:
Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor
gene. Nature. 432:775–779. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Choi Y, Kim H, Chung H, Hwang JS, Shin JA,
Han IO and Oh ES: Syndecan-2 regulates cell migration in colon
cancer cells through Tiam1-mediated Rac activation. Biochem Biophys
Res Commun. 391:921–925. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Park H, Kim Y, Lim Y, Han I and Oh ES:
Syndecan-2 mediates adhesion and proliferation of colon carcinoma
cells. J Biol Chem. 277:29730–29736. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Huang JW and Chuang NN: Shift syndecan-2
from RACK1 to caveolin-2 upon transformation with oncogenic ras.
Biochem Biophys Res Commun. 350:227–232. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Orosco A, Fromigué O, Haÿ E, Marie PJ and
Modrowski D: Dual involvement of protein kinase C delta in
apoptosis induced by syndecan-2 in osteoblasts. J Cell Biochem.
98:838–850. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Munesue S, Yoshitomi Y, Kusano Y, Koyama
Y, Nishiyama A, Nakanishi H, Miyazaki K, Ishimaru T, Miyaura S,
Okayama M and Oguri K: A novel function of syndecan-2, suppression
of matrix metalloproteinase-2 activation, which causes suppression
of metastasis. J Biol Chem. 282:28164–28174. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huang X, Xiao DW, Xu LY, Zhong HJ, Liao
LD, Xie ZF and Li EM: Prognostic significance of altered expression
of SDC2 and CYR61 in esophageal squamous cell carcinoma. Oncol Rep.
21:1123–1129. 2009.PubMed/NCBI
|
|
29
|
Marzioni D, Lorenzi T, Mazzucchelli R,
Capparuccia L, Morroni M, Fiorini R, Bracalenti C, Catalano A,
David G, Castellucci M, et al: Expression of basic fibroblast
growth factor, its receptors and syndecans in bladder cancer. Int J
Immunopathol Pharmacol. 22:627–638. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Popović A, Demirović A, Spajić B, Stimac
G, Kruslin B and Tomas D: Expression and prognostic role of
syndecan-2 in prostate cancer. Prostate Cancer Prostatic Dis.
13:78–82. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim Y, Park H, Lim Y, Han I, Kwon HJ,
Woods A and Oh ES: Decreased syndecan-2 expression correlates with
trichostatin-A induced-morphological changes and reduced
tumorigenic activity in colon carcinoma cells. Oncogene.
22:826–830. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Han I, Park H and Oh ES: New insights into
syndecan-2 expression and tumourigenic activity in colon carcinoma
cells. J Mol Histol. 35:319–326. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Choi S, Kim Y, Park H, Han IO, Chung E,
Lee SY, Kim YB, Lee JW, Oh ES and Yi JY: Syndecan-2 overexpression
regulates adhesion and migration through cooperation with integrin
alpha2. Biochem Biophys Res Commun. 384:231–235. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Oh T, Kim N, Moon Y, Kim MS, Hoehn BD,
Park CH, Kim TS, Kim NK, Chung HC and An S: Genome-wide
identification and validation of a novel methylation biomarker,
SDC2, for blood-based detection of colorectal cancer. J Mol Diagn.
15:498–507. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ma L, Qin G, Gai F, Jiang Y, Huang Z, Yang
H, Yao S, Du S and Cao Y: A novel method for early detection of
colorectal cancer based on detection of methylation of two
fragments of syndecan-2 (SDC2) in stool DNA. BMC Gastroenterol.
22:1912022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bach S, Paulis I, Sluiter NR, Tibbesma M,
Martin I, van de Wiel MA, Tuynman JB, Bahce I, Kazemier G and
Steenbergen RDM: Detection of colorectal cancer in urine using DNA
methylation analysis. Sci Rep. 11:23632021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhao G, Ma Y, Li H, Li S, Zhu Y, Liu X,
Xiong S, Liu Y, Miao J, Fei S, et al: A novel plasma based early
colorectal cancer screening assay base on methylated SDC2 and
SFRP2. Clin Chim Acta. 503:84–89. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang J, Liu S, Wang H, Zheng L, Zhou C, Li
G, Huang R, Wang H, Li C, Fan X, et al: Robust performance of a
novel stool DNA test of methylated SDC2 for colorectal cancer
detection: A multicenter clinical study. Clin Epigenetics.
12:1622020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Han YD, Oh TJ, Chung TH, Jang HW, Kim YN,
An S and Kim NK: Early detection of colorectal cancer based on
presence of methylated syndecan-2 (SDC2) in stool DNA. Clin
Epigenetics. 11:512019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Oh TJ, Oh HI, Seo YY, Jeong D, Kim C, Kang
HW, Han YD, Chung HC, Kim NK and An S: Feasibility of quantifying
SDC2 methylation in stool DNA for early detection of colorectal
cancer. Clin Epigenetics. 9:1262017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lin PC, Lin JK, Lin CH, Lin HH, Yang SH,
Jiang JK, Chen WS, Chou CC, Tsai SF and Chang SC: Clinical
relevance of plasma DNA methylation in colorectal cancer patients
identified by using a genome-wide high-resolution array. Ann Surg
Oncol. 22 (Suppl 3):S1419–S1427. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hua Y, Ma X, Liu X, Yuan X, Qin H and
Zhang X: Abnormal expression of mRNA, microRNA alteration and
aberrant DNA methylation patterns in rectal adenocarcinoma. PLoS
One. 12:e01744612017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Stöhr H, Mohr N, Fröhlich S, Mehdi SQ,
Bhattacharya SS and Weber BHF: Cloning and characterization of
WDR17, a novel WD repeat-containing gene on chromosome 4q34.
Biochim Biophys Acta. 1579:18–25. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
van der Zee RP, van Noesel CJM, Martin I,
Ter Braak TJ, Heideman DAM, de Vries HJC, Prins JM and Steenbergen
RDM: DNA methylation markers have universal prognostic value for
anal cancer risk in HIV-negative and HIV-positive individuals. Mol
Oncol. 15:3024–3036. 2021. View Article : Google Scholar : PubMed/NCBI
|
